AstraZeneca’s CEO, a French-born Australian running an Anglo-Swedish company, is betting $50 billion on a strategy of making the US its largest market — while also pouring $15 billion into China. Each ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth-quarter 2025 investor letter. It is a diversified fund that focuses on long-term capital appreciation by ...

AstraZeneca PLC aims for $80 billion in revenue by 2030, driven by strong growth in oncology, biopharmaceuticals, and rare diseases, despite recent share price declines. The company's weight ...

AstraZeneca PLC (NASDAQ:AZN) is one of the best immunotherapy stocks to buy according to hedge funds. AstraZeneca PLC (NASDAQ:AZN) received an update from Deutsche Bank on February 16, with the firm ...

AstraZeneca has an even larger exposure to oncology, with the segment contributing about 44% of total revenues. Outside of oncology, AstraZeneca has meaningful positions in immuno ...

AstraZeneca will push the pill, elecoglipron, into a comprehensive late-stage program that will test the drug as a monotherapy, as part of a combination regimen and for several indications.

AstraZeneca PLC (NASDAQ:AZN) is one of the stocks in focus on Jim Cramer’s game plan. Cramer mentioned the company during the ...

Gov. Glenn Youngkin announced Thursday that global pharmaceutical manufacturer and biotech company AstraZeneca will invest $4.5 billion to establish two new manufacturing facilities in Albemarle ...

Pharmaceutical giant AstraZeneca is suing Utah’s attorney general and insurance commissioner over a law passed during the legislative session aimed at stopping drug manufacturers from limiting where ...

The pharmaceutical giant announced profit in line with expectations and revenue that slightly beat forecasts on Tuesday.

LONDON - AstraZeneca’s COVID-19 vaccine provided strong protection against disease and complete protection against hospitalization and death across all age groups in a late-stage U.S. study, the ...

LONDON (Reuters) - AstraZeneca is spinning off six early-stage experimental drugs into a new $250 million standalone biotech company focused on severe autoimmune diseases. The spin-off of the three ...